Loss of function mutations and deletions encompassing the plant homeodomain finger 6 (PHF6) gene are present in about 20% of T-cell acute lymphoblastic leukemias (ALLs). Here, we report the identification of recurrent mutations in PHF6 in 10/353 adult acute myeloid leukemias (AMLs). Genetic lesions in PHF6 found in AMLs are frameshift and nonsense mutations distributed through the gene or point mutations involving the second plant homeodomain (PHD)-like domain of the protein.
Introduction
Acute myeloid leukemia (AML) consists of a heterogeneous group of aggressive neoplasms that is characterized by clinical and genetic heterogeneity and shows an increasing incidence with age. 1 Insights in the molecular genetic basis of AML initially came from the characterization of recurrent chromosomal rearrangements, including t(8;21), t (15;17) , inv (16) and different 11q23 translocations. 2 Such clonal chromosome aberrations are detectable in the leukemic blasts of B55% of adults with AML and have been recognized as important prognostic factors. Moreover, the characterization of genes located in the breakpoints of these rearrangements identified critical fusion oncogenes involved in the pathogenesis of AML including RUNX1-MTG8/AML1-ETO, PML-RARA, CBFB/SMMHC and MLL-AF9. Subsequently, intense sequencing efforts of specific candidate genes, including NPM1, FLT3, CEBPA, MLL, NRAS, WT1, RUNX1, NF1 and TET2, further broadened the spectrum of genetic lesions toward a wide variety of somatic mutations implicated in AML pathogenesis. [2] [3] [4] [5] Finally, sequencing of complete AML genomes 6, 7 revealed the presence of new somatically acquired mutations and led to the identification of recurrent mutations in the IDH1 and IDH2 genes. 8, 9 Recently, we identified the plant homeodomain finger 6 (PHF6) gene as a new tumor suppressor in T-cell acute lymphoblastic leukemia (T-ALL).
10 PHF6 deletions and inactivating mutations are found in about 20% of T-ALL samples and are present almost exclusively in male leukemia cases. 10 Notably, PHF6 mutations were not identified in precursor B-lineage ALL samples, suggesting that loss of PHF6 might be restricted to lymphoid tumors of the T-cell lineage. 10 In the past, detailed molecular characterization of T-ALL and AML revealed a number of common genetic lesions shared by these hematological tumors including the CALM-AF10 and NF1. 23 Given these similarities, we hypothesized that mutational loss of PHF6 might also be implicated in the pathogenesis of specific subtypes of AML. To address this question, we sequenced all coding exons of PHF6 in a cohort of 353 AML patients. In addition, we used real-time quantitative DNA polymerase chain reaction (PCR) to assess the presence of genomic PHF6 deletions in 41 cases. The results of this analysis show the presence of recurrent loss of function mutations in PHF6 in AML and characterize the spectrum of associated genetic alterations cooperating with PHF6 loss in myeloid malignancies.
Materials and methods

Patient samples
Leukemic DNA and cryopreserved lymphoblast samples were provided by collaborating institutions in the US (Eastern Cooperative Oncology Group (ECOG) and Memorial Sloan-Kettering Cancer Center (MSKCC)), Spain (Hospital Central de Asturias, Oviedo) and Belgium (Department of Pediatric Hemato-Oncology, Leuven University Hospital, Leuven). All samples were collected with informed consent and under the supervision of local IRB.
Sequence analysis PHF6 mutations were analyzed by PCR amplification of PHF6 exons 2-10 followed by direct bidirectional DNA sequencing as previously described. 10 Sequence analysis of IDH1, IDH2, TET2, ASXL1, FLT3, NPM1, CEBPA, WT1, KRAS and NRAS was performed as previously described. 24 Sorting of hematopoietic stem cell, myeloid progenitor and lymphoid populations Murine bone marrow, thymus and spleen cells were sorted using a Dako Cytomation Mo-Flo Fluorescence Activated Cell Sorter. Antibody staining was performed as previously described. 25 The antibodies used for sorting included c-kit (2B8), Sca-1 (D7), Mac-1 (M1/70), Gr-1 (RB6-8C5), NK1.1 (PK136), TER-119, CD3 (145-2C11), CD4 (L3T4), CD8a (53-6.7), CD19 (1D3), IgM (II/41), IL7Ra (A7R34), CD25 (PC61), TCRb (H57-597), CD34 (RAM34), FcgRII/III (2.4G2), CD150 (9D1) and were purchased from BD-Pharmingen (San Diego, CA, USA) or e-Bioscience (San Diego, CA, USA). The bone marrow lineage cocktail included antibodies against Mac-1, Gr-1, NK1.1, TER-119, CD3 and CD19. Sorted hematopoietic stem cell (HSC) populations included total LSK (lin
Quantitative real-time PCR
RNA preparation of sorted cell population was achieved using the RNeasy plus mini kit (QIAGEN, Valencia, CA, USA) according to the manufacturer's protocol. cDNA was generated with the ThermoScript reverse transcriptase (RT)-PCR system (Invitrogen, Carlsbad, CA, USA) and analyzed by quantitative real-time PCR using the SYBR Green RT-PCR Core Reagents kit (Applied Biosystems, Carlsbad, CA, USA) and the 7300 RealTime PCR System (Applied Biosystems). Phf6 expression levels were calculated using Gapdh as reference. PCR primers sequences are available upon request.
Real-time quantification of DNA copy number
Real-time quantitative DNA PCR analysis was performed to screen AML cases for the presence of genomic PHF6 deletions using the FastStart Universal SYBR Green Master Mix (Roche, Basel, Switzerland) and the 7300 Real-Time PCR System (Applied Biosystems) as previously described 10 using TIE2 as control gene. Data were analyzed using the comparative ddCT method (Applied Biosystems).
Statistical analysis
The Fisher's exact test was used to compare the frequency of PHF6 mutations between male and female AML patients.
Results
PHF6 mutations in adult AML
PHF6 was recently identified as a novel X-linked tumor suppressor gene recurrently mutated and deleted in pediatric and adult T-ALL. 10 To evaluate whether PHF6 inactivation might also contribute to the pathogenesis of AML, we sequenced all coding exons of PHF6 and used real-time quantitative DNA PCR to assess the presence of genomic PHF6 deletions in AML samples. DNA sequencing analysis of PHF6 in AML revealed the presence of PHF6 mutations in 10/353 (3%) AMLs analyzed. Most PHF6 mutations present in AMLs were characteristically loss of function alleles with three nonsense and four frameshift truncating mutations (Figures 1a and b) . In addition, we identified three missense mutations located in the N-terminal region (A40G) and the second PHD2 domain (H302Y and H329L) of PHF6 (Figures 1a and b) . DNA copy number analysis of the PHF6 locus failed to detect any genomic PHF6 deletions in 41 AML (22 males and 19 females) cases analyzed.
Cooperative genetic lesions in PHF6-mutated adult AML PHF6-mutated AML cases in this series, corresponded to the French-American-British classification (FAB) subtype's M0, M1 and M2, or presented as a secondary AML (Table 1) . At the genetic level, AML is a heterogeneous disease characterized by the accumulation of acquired somatic genetic lesions that cooperate in the transformation of myeloid progenitor cells. In order to identify genetic defects that might cooperate with PHF6 inactivation in the pathogenesis of AML, we sequenced IDH1, IDH2, TET2, ASXL1, FLT3, NPM1, CEBPA, WT1, KRAS and NRAS, in PHF6-mutated AML samples. This analysis revealed mutations affecting IDH2, ASXL1, FLT3, CEBPa and NRAS as additional genetic events that may cooperate with PHF6 inactivation in the pathogenesis of AML (Table 1 ).
Phf6 expression in murine HSC, myeloid progenitor and lymphoid populations PHF6 is highly conserved among vertebrates 26 and shows ubiquitous expression in a wide variety of human tissues. 10, 26 The presence of recurrent mutations in PHF6 in AML suggests a possible role of this tumor suppressor gene in the control of myeloid development. In order to evaluate Phf6 expression in HSCs, lymphoid and myeloid progenitors, we performed quantitative RT-PCR analysis of sorted mouse myeloid progenitor and lymphoid cell populations. These analyses revealed ubiquitous but slightly lower expression levels of Phf6 transcripts in HSC and myeloid cell progenitor populations as compared with different subsets of lymphoid cells (Figure 2 ). Within the myeloid progenitor populations, we noticed higher Phf6 levels in LSK progenitors compared with common myeloid progenitor and granulocyte-macrophage progenitor populations (Figure 2 ). The murine thymocyte populations at different stages of development showed a similar pattern of variable Phf6 expression as previously identified in human T-cell subsets. 
PHF6 mutations are characteristically present in male patients with AML
One of the most notorious features of PHF6 mutations in T-ALL is that they are almost exclusively found in male patients with this disease, 10 which may explain in part the 3:1 higher prevalence of T-ALL in males than in females. Notably, although to a less extent than in T-ALL, AML is also more frequently found in males with a male-to-female ratio of 1.3:1. 27 Analysis of the gender distribution in PHF6-mutated AML patients demonstrated that genetic alterations in PHF6 are seven times more frequent in male (9/195; 4.6%) than in female (1/158; 0.6%) AML patient samples (Po0.05; Figure 3 ).
Discussion
The PHF6 tumor suppressor gene encodes a plant homeodomain (PHD) protein containing four nuclear localization signals and two imperfect PHD zinc-finger domains, 28 with a proposed role in transcriptional regulation and/or chromatin remodeling. 26, 28 Inactivating mutations in PHF6 cause the Bö rjeson-Forssman-Lehman syndrome, 29 a relatively uncommon type of X-linked mental retardation that mainly affects Abbreviations: AML, acute myeloid leukemia; PHF6, plant homeodomain finger 6; TKD, tyrosine kinase domain mutation; ITD, internal tandem duplication. *Biphenotypic T-myeloid leukemia. males, and shows milder clinical features in affected carrier females.
30
A recent report described a male Bö rjeson-Forssman-Lehman syndrome patient that developed T-ALL, suggesting that Bö rjeson-Forssman-Lehman syndrome represents a cancer predisposition syndrome. 31 In this study, we evaluated whether mutational loss of PHF6 might also be implicated in the pathogenesis of adult AML and identified PHF6 mutations in B3% (10/353) of adult AML samples analyzed. PHF6-mutated primary AML cases were predominantly immature leukemias (FAB subtypes M0-M2); however, they showed definite AML immunophenotypes. Only in one case, retrospective analysis of one of the PHF6-mutated AML M0 samples showed weak cytoplasmic CD3 positivity, together with 8% myeloperoxidase-positive blasts and CD15/ CD33 expression. Moreover, the presence of additional cooperative mutations affecting prototypical AML-associated oncogenes and tumor suppressor genes such as IDH2, ASXL1, FLT3, CEBPa and NRAS (Table 1) , in PHF6-mutated AML cases, further confirms the true myeloid nature of these samples.
Nonsense and frameshift PHF6 mutations accounted for 70% (7/10) of all PHF6 mutations identified in our series and were distributed throughout the complete PHF6 gene (Figures 1a and  b) . Missense mutations accounted for the remaining 30% (3/10) of PHF6 lesions and mainly involved the second PHD-like zincfinger domain of the PHF6 protein (Figures 1a and b) . This includes an amino-acid substitution (A40G) in the N-terminus region of PHF6, a variant that was unique among 546 hematologic tumors analyzed in our laboratory. However, no remission material was available to test the somatic origin of this change. Thus, this particular variant may correspond to a novel point mutation disrupting the tumor suppressor function of PHF6 or alternatively correspond to a previously unreported polymorphism. Notably, the other two missense mutations found in AML involved residues R319 and H329 located in the second PHD-like domain of PHF6 (Figures 1a and b; Table 1 ), which have been previously found mutated in T-ALL, 10 further strengthening the idea that the second PHD-like domain may mediate critical tumor suppressor functions of PHF6. 10 Overall, our results identify PHF6 as an X-linked tumor suppressor gene that is mutated in a fraction of both de novo as well as secondary adult AMLs. PHF6 mutations occur at a lower frequency in AML compared with T-ALL, but target mainly male patients in both hematological malignancies. The prognostic impact of PHF6 mutations in AML will need to be assessed in larger cohorts of patients collected on multicenter clinical trials. In addition, these results suggest the possibility that PHF6 mutations might occur in male patients with other myeloid malignancies, such as myelodysplasia or myeloproliferative disorders, which should be the addressed in future studies. Award Recipient of the Howard Hughes Medical Institute. AF is a Leukemia and Lymphoma Society Scholar. We appreciate the assistance of Adriana Heguy with DNA resequencing.
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